Navigation Links
Drug Used in Coronary Artery Bypass Surgery may Increase Risk of Death

Aprotinin, a drug used for limiting blood loss in patients undergoing cardiac surgery, is associated with an increased risk of death during five years following// the surgery, according to a new study.

Aprotinin was first approved for use in high-risk patients needing coronary artery surgery in the United States in 1993. As background information in the article, the authors state that more than 4 million patients worldwide have received aprotinin since 1985, principally during cardiac surgery. Annual use has increased to 600,000 patients (2005) throughout the world, including 246,000 uses in the United States in the past year. The safety of aprotinin came under scrutiny in 2006. An "observational study reported that aprotinin use was associated with a doubling to tripling of the risk of perioperative renal [kidney] dysfunction and failure requiring dialysis in patients undergoing primary, repeat or complex coronary artery surgery."

Dennis T. Mangano, Ph.D., M.D., from the Ischemia Research and Education Foundation, San Bruno, Calif., and colleagues assessed survival rates at six weeks, six months and annually for five years for 3,876 patients undergoing coronary artery bypass graft (CABG) surgery at 62 medical centers around the world. The researchers examined death rates of these patients according to the use of three medications used to lessen bleeding—aminocaproic acid and tranexamic acid, aprotinin, or no anti-bleeding agent.

"During five years, 223 deaths occurred among 1,072 aprotinin-treated patients (20.8 percent), a death rate nearly two-thirds greater than control patients (128 deaths among 1,009 patients, 12.7 percent)," the researchers found. "Rates were similar for aminocaproic acid patients (132 deaths among 834 patients, 15.8 percent) and for tranexamic acid patients (65 deaths among 442 patients, 14.7 percent)."

"We estimate that over the past year, aprotinin was prescribed worldwide to at least 200,00
'"/>




Page: 1 2

Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
2. Coronary stent leads to complications
3. Coronary heart disease bids Adieu
4. Older Men Surviving Coronary Bypasses
5. The Link Between Oxidized Phospholipids And Coronary Artery Disease
6. Cigarette Smoking Leads To Development Of Type 2 Diabetes In Patients With Coronary Artery Disease
7. New Cardiac Angiography Technique For Improved Imaging Of Coronary Veins
8. Effectiveness Of Drug-Releasing Coronary Stents
9. Children Are At The Risk Of Inheriting Coronary Disease
10. Statin Therapy in Patients with Acute Coronary Syndrome Improves Survival
11. Meditation may Improve Cardiac Risk Factors in Patients with Coronary Heart Disease
Post Your Comments:
(Date:10/7/2008)...r Center at the University of California, San Dieg...elentless march of advanced lung cancer by treatin...ile many vaccines attempt to pump up the immune sy...ix, is genetically engineered to also trick the ca...g activities. , The first patients have begun en...
(Date:10/7/2008)...ewswire/ -- Van Wert County Hospital, Van,Wert, Oh... LOGICARE(R),Corp.,s newest Emergency Department a...ospital joins Conway Regional Medical Center, Conw...enter, Nashua, New Hampshire,in using OnRecord(TM... Wert County Hospital began using OnRecord(TM) for...
(Date:10/7/2008)...how signs of awareness, unlike vegetative state ,...everely brain-damaged patients in a "minimally con...killing treatment, according to European researche...ferent than a persistent vegetative state (PVS), w...f or surroundings. MCS patients do show some evide...
(Date:10/7/2008)...ess, more choices for Indiana healthcare ... Oct. 7 /PRNewswire/ -- Lutheran Health Network (L...with Consumers Life Insurance,Company forming a ne...rs in,12 Indiana counties including the Fort Wayne...s Fort Wayne,s Lutheran,Hospital, the region,s onl...
Breaking Medicine News(10 mins):Health News:Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center 2Health News:Latest LOGICARE(R) EDIS User Sees 'Tremendous Results' 2Health News:Patients in Minimally Conscious State May Still Feel Pain 2Health News:Consumers Life Expands Healthcare Network in Northeast Indiana 2
...an regulators told a Congressional panel today tha...an growth hormones -- are simple enough// to produ... to be safely duplicated. Generic versions of cer...rope for the last four years, but approval came on...
... is proposed to be passed in South Carolina, which...l if they donate their kidneys//. If this bill is ...stay in the jail by as many as 180 days. Democrat...nding this legislation opines that the passing of ...
... The battle against polio is far from over in Biha...rming jump in the infectious disease// in a state ...s sad to admit that seven new polio cases surfaced...st week of February, despite the immunisation driv...
...n’t have to fly long miles by economy class, to ...arch has brought out a startling high risk// of th..., right here among us, in IT offices, call centers...chard Beasley of New Zealand's privately funded Me...
Other Medicine News:Health News:Caution Urged on Biologic Drugs 2Health News:Seven Polio Cases Detected in Bihar 2
(Date:10/7/2008)...lts of FLEXX Trial Presented at the Osteoarthritis...ess, PARSIPPANY, N.J., Oct. 7 /- Fer...ts from the FLEXX Trial of Osteoarthritis of the,K...te), a highly pure,non-avian high molecular weight...is superior to intra-articular saline (IA-saline) ...
(Date:10/7/2008)... COLLINS, Colo., Oct. 7 /- A study pu... embryonic stem cell self-renewal,reported that I...ecombinant,human serum albumin) was an effective r...ure., The article entitled, "The ground state of ...researchers used Cellastim as a recombinant,albumi...
(Date:10/7/2008)...ent, Prospective Randomized Placebo-Controlled Pha...nt Improved Overall Survival., MOUNTAIN VIEW, Cal...eutics has now evaluated the mature Phase II data ...date PROSTVAC(TM) that had been,obtained as part o...al,Cancer Institute (NCI) in the US., The results...
(Date:10/6/2008)...O and CHIPPENHAM, England, October 7 /PRNewswire-F... Mothers Index: 4565) and Vectura,Group plc ("Vect...studies,evaluating the efficacy, safety and tolera...of the European Respiratory Society (ERS) in Berli...rronium bromide), a novel,inhaled long-acting musc...
Breaking Medicine Technology:Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5North Americas northernmost lake affected by global warming 571 1North Americas northernmost lake affected by global warming 571 2TIGroup Names Dennis M Smith as Chief Financial Officer 2083 1TIGroup Names Dennis M Smith as Chief Financial Officer 2083 2TIGroup Names Dennis M Smith as Chief Financial Officer 2083 3TIGroup Names Dennis M Smith as Chief Financial Officer 2083 4Agendia Joins the Personalized Medicine Coalition 28PMC 29 852 1Agendia Joins the Personalized Medicine Coalition 28PMC 29 852 2Beaumont Technology Usability Center To Offer Training For Medical Technology Companies 847 1Beaumont Technology Usability Center To Offer Training For Medical Technology Companies 847 2
...lood Glucose,Control and Progressive Weight Loss -... Amylin,Pharmaceuticals, Inc. and Eli Lilly and Co...owed BYETTA(R) (exenatide) injection,sustained imp...ight,loss through three and a half years of therap...vements in cardiovascular risk,factors in people w...
...2007--Gilead,Sciences, Inc. (Nasdaq:GILD) today an... evaluating the company,s once-daily,anti-HIV drug...ovir,DF) 300 mg as a potential treatment for chron...ary efficacy endpoint. The data show,that Viread i...al,drug Hepsera(R) (adefovir dipivoxil) among pati...
Other Medicine Technology:Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6
Conventional Digitally-Controlled Water Baths
...the Flavavirus group pf viruses. This virus is fou...ngue fever are the sudden onset of fever, headache...ulopapular rash and retrobulbar pain.,This test is...agnosis of anti-Dengue IgM antibodies. The Bio-Qua...
...the Flavavirus group pf viruses. This virus is fou...ngue fever are the sudden onset of fever, headache...ulopapular rash and retrobulbar pain.,This test is...agnosis of anti-Dengue IgG antibodies. The Bio-Qua...
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance.
Medicine Products: